Only one patient required a switch to another biologic agent: a 67-year-old male with a difficult-to-treat ankylosing spondylitis with multiple flares of uveitis long term before the use of secukinumab, even as a paradoxical event during adalimumab treatment; this patient suffered three more flares of bilateral uveitis during IL-17 inhibitor and required local intraocular glucocorticoids without complete recovery. The gene discussed is IL17A; the disease is ankylosing spondylitis.